Eli Lilly and Company’s (NYSE:LLY) projected Monday release of Solaezumab causes Credit Suisse to foresee positive risk and reward. Downside risk is calculated at 5 percent with the upside potential at 10 percent, but the analyst says that shares are most likely to be flat on the results; they are rated Outperform with a price target of $54.
Glu Mobile (NASDAQ:GLUU) should meet its third quarter guidance, says Canaccord, but not a lot of upside should be expected. The analyst expects a fourth quarter heavy launch timetable to bring in a strong quarter, but a low probability that Glu will raise its guidance. Shares are rated Buy with a price target of $7.
Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>
FedEx Corporation (NYSE:FDX) has RBC Capital being cautious on the company going into its analyst day on October 9th and 10th because of concerns that management’s guidance on the Express restructuring could turn out insufficient to materially move the shares. Moreover, RBC believes that FedEx might allot little time to its USPS Priority Mail contract as that process has yet to fully play out. RBS maintains a Sector Perform on FedEx.
Sarepta Therapeutics (NASDAQ:SRPT) remains undervalued, says Lazard Capital, even after the significant rally on Wednesday. The analyst believes that eteplirsen is likely well positioned for accelerated approval, raising its price target for shares to $54.
Hewlett-Packard Company’s (NYSE:HPQ) strategy remains unclear to Jefferies after Wednesday’s analyst meeting, thus the firm reiterates an Underperform on shares with a reduced price target of $12. It should be noted that Deutsche Bank reduced its price target for to $10 on Thursday morning.
Don’t Miss: Will HP Ever Find Its Footing Under Whitman?